Discover
TARA
Protara Therapeutics, Inc.
3.55
2 x 2.92
2 x 5.12
bid
ask
-
0.15
4.05%
2 @ 04:00 PM
3.62 +0.07 (1.97%)
| Ytd | -33.40% | |
| 1y | 10.59% |
3.45
day range
3.73
3.45
52 week range
7.82
| Open | 3.69 | Prev Close | 3.70 | Low | 3.45 | High | 3.73 | Mkt Cap | 209.79M |
| Vol | 3.95M | Avg Vol | 585.78K | EPS | -1.36 | P/E | N/A | Forward P/E | -1.61 |
| Beta | 1.79 | Short Ratio | 14.46 | Inst. Own | 51.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-10 | 50-d Avg | 3.95 | 200-d Avg | 4.99 | 1yr Est | 26.40 |
| Income Statement | |||
| Operating Expenses | 23.32M | ||
| Research and Development Expense | 16.95M | ||
| Selling, General and Administrative Expense | 6.37M | ||
| Operating Income | -23.32M | ||
| Net Income | -21.67M | ||
| Net Income Common Stock | -21.67M | ||
| Net Income Common Stock (USD) | -21.67M | ||
| Consolidated Income | -21.67M | ||
| Earnings per Basic Share | -0.36 | ||
| Earnings per Basic Share (USD) | -0.36 | ||
| Earnings per Diluted Share | -0.36 | ||
| Earning Before Interest & Taxes (EBIT) | -21.67M | ||
| Earning Before Interest & Taxes (USD) | -21.67M | ||
| Weighted Average Shares | 61.01M | ||
| Weighted Average Shares Diluted | 61.01M | ||
| Balance Sheet | |||
| Cash and Equivalents | 17.08M | ||
| Cash and Equivalents (USD) | 17.08M | ||
| Investments | 145.52M | ||
| Investments Current | 125.42M | ||
| Investments Non-Current | 20.10M | ||
| Current Assets | 146.15M | ||
| Property, Plant & Equipment Net | 3.92M | ||
| Total Assets | 176.09M | ||
| Debt Current | 1.29M | ||
| Total Debt | 2.75M | ||
| Current Liabilities | 13.32M | ||
| Debt Non-Current | 1.46M | ||
| Total Liabilities | 14.78M | ||
| Accumulated Retained Earnings (Deficit) | -341.87M | ||
| Accumulated Other Comprehensive Income | -363.00K | ||
| Shareholders Equity | 161.31M | ||
| Shareholders Equity (USD) | 161.31M | ||
| Assets Non-Current | 29.94M | ||
| Total Debt (USD) | 2.75M | ||
| Liabilities Non-Current | 1.46M | ||
| Trade and Non-Trade Payables | 4.66M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 72.00K | ||
| Net Cash Flow from Financing | -26.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 2.34M | ||
| Capital Expenditure | -332.00K | ||
| Net Cash Flow from Investing | 17.75M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 18.09M | ||
| Net Cash Flow from Operations | -15.39M | ||
| Share Based Compensation | 1.38M | ||